Events 2010

[August 15-20, 2010]
ICOPA 2010 – Melbourne, Australia
The Drugs for Neglected Diseases initiative (DNDi) participated in several activities at the
XIIth International Congress of Parasitology (ICOPA) 2010: the organisation of two symposia,
 (on Malaria and on Drug Discovery), as well as a preview of the documentary "1$ for 1 life".


DNDi Symposia

•    Tuesday, August 17, 2010 (10:30am—12:00)

Title: Artesunate-based combination treatments for malaria

Chairs: Dr. Visweswaran Navaratman (DNDi Malaysia) and Dr. Bernhards Ogutu (Kenya Medical Research Institute)

(click on the link to read the abstract)

Speakers:
Dr. Elisabeth Ashley (Imperial College NHS Trust, UK):  Artesunate-mefloquine: past, present and future 
Dr. Stephan Duparc (Medicines for Malaria Venture, Switzerland): Pyramax® (pyronaridine/artesunate), tablet or paediatric sachet, versus Coartem® (artemether/lumefantrine), tablet or crushed tablet, in patients with acute uncomplicated Plasmodium falciparum malaria: results of two pivotal phase III studies 
Dr. François Bompart (sanofi-aventis, France): ASAQ: New data and post registration study plan progress
Prof. Umberto d’Alessandro (Prince Leopold Institute of Tropical Medicine, Belgium): Dihydroartemisinin-piperaquine: an update


•    Tuesday, August 17, 2010 (1:45pm—3:15pm)

Title: The DNDi model for drug discovery programs of neglected diseases

Chairs: Prof. Simon Croft (London School of Hygiene & Tropical Medicine, UK) and Prof. Susan Charman (Monash Institute of Pharmaceutical Sciences, Australia)

Speakers:
Dr. Robert Don (DNDi, Switzerland): The DNDi model: from screening through lead optimization programmes to preclinical candidates
Dr. Shing Chang (DNDi, Switzerland): Fexinidazole: a new oral drug for the treatment of human African trypanosomiasis
Dr. Bob Jacobs (Scynexis, USA): SCYX 7158: chemistry background and new findings
Dr. Denis Martin (DNDi, Switzerland): Identification and development of New Chemical Entities to treat visceral leishmaniasis: a bumpy road
Dr. Martine Keenan (Epichem, Australia): Novel compounds for the treatment of Chagas disease
Dr. Lucio Freitas-Junior (Institut Pasteur Korea, Rep. South Korea): Phenotypic high-throughput screening for kinetoplastids